Open Versus Core Needle Biopsy in Lower-Extremity Sarcoma: Current Practice Patterns and Patient Outcomes

• Published in: Journal of bone and joint surgery. American volume 2023-07, Vol.105 (Suppl 1), p.57-64
• Main Authors: Burke, Zachary D.C., Lazarides, Alexander L., Gundavda, Manit K., Griffin, Anthony M., Tsoi, Kim M., Ferguson, Peter C., Wunder, Jay S.
• Format: Article
• Language: English
• Subjects: Biopsy, Large-Core Needle - adverse effects; Biopsy, Large-Core Needle - methods; Extremities - pathology; Humans; Prospective Studies; Retrospective Studies; Sarcoma - pathology; Sarcoma - surgery; Soft Tissue Neoplasms - pathology; Soft Tissue Neoplasms - surgery
• ISSN: 0021-9355; 1535-1386
• DOI: 10.2106/JBJS.22.01259

Historically, open biopsy (OB) was the gold standard for sarcoma diagnosis. Core needle biopsy (CNB) has become increasingly common. There are limited data evaluating how the type of biopsy impacts definitive surgical resection or postoperative outcomes. The aims of this study were to (1) characterize current international biopsy practice patterns, and (2) evaluate how the type of biopsy performed impacts the resection surgery, infection risk, oncological complications, and patient-reported functional outcome scores. This study was a preplanned secondary analysis of the prospective, multicenter PARITY (Prophylactic Antibiotic Regimens in Tumor Surgery) study. Patients with a benign diagnosis, metastatic disease, or no biopsy prior to surgery were excluded. Prospectively collected demographic, biopsy, surgical, and outcome variables were analyzed, and differences between patients undergoing OB and CNB were assessed. Parametric and nonparametric tests were used to compare variables between groups, and the Cox proportional hazards method was used to compare infection-related and oncological outcomes at 1 year. Median functional outcome scores at 1 year were compared. Four hundred and sixty-four patients met the inclusion criteria. Data were collected from 48 sarcoma centers in 12 countries. CNB was the more utilized biopsy modality overall (57.5%). OB was more common in the U.S. and Canada. The median operative time was significantly longer for patients who underwent OB (324 versus 260 minutes; p < 0.001). Significantly more skin (p < 0.001) and fascial tissue (p < 0.001) were excised in the OB group, which also had a lower rate of primary closure (86.3% versus 92.9%; p = 0.03). There were no differences in surgical site infection or oncological outcomes between the groups at 1-year follow-up. CNB was the more common biopsy modality in the PARITY study in most countries. However, OB was more common in the U.S. and Canada. Patients undergoing OB had longer operative times, more excised tissue, and lower rates of primary closure, but this did not translate to differences in infection rates or oncological outcomes, including local recurrence. Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.